GUTS
FRACTYL HEALTH, INC.
NASDAQ · Healthcare · Biotechnology · US
$0.59
−0.80%Sep 15, 2026, 14:48 UTC
SueWallSt reminded shareholders of an October 20, 2026 lead plaintiff deadline in the securities class action lawsuit against Fractyl Health, Inc. (GUTS), in which CEO Harith Rajagopalan and former CFO Lisa A. Davidson face Section 20(a) control person claims over allegedly overstated Revita DMR efficacy data.
Source:Sep 3, 2026, 14:40 UTC
A class action lawsuit was filed against Fractyl Health, Inc. on behalf of investors who purchased securities between January 13, 2025 and January 29, 2026.
Sep 1, 2026, 16:00 UTC
Glancy Prongay Wolke & Rotter LLP announced a securities fraud lawsuit on behalf of Fractyl Health, Inc. shareholders who suffered losses, related to the company's disclosure of REMAIN-1 Midpoint Cohort data on January 29, 2026.
Source:Aug 14, 2026, 09:04 UTC
Fractyl Health launched a clinical trial for its Rejuva gene therapy, a one-time treatment for obesity and type 2 diabetes.
Source:Aug 10, 2026, 23:05 UTC
Fractyl Health announced that its Revita endoscopic procedure demonstrated durable weight-maintenance results one year after patients discontinued GLP-1 therapy.
Source:Jul 15, 2026, 13:03 UTC
Fractyl Health reported one-year data from the REMAIN-1 study showing its Revita procedure helped patients maintain weight loss after stopping GLP-1 therapy.
Source: